Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peripheral arterial disease who benefit from optimal prevention strategy including clopidogrel

Trial Profile

Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peripheral arterial disease who benefit from optimal prevention strategy including clopidogrel

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Cilostazol; SL 650472
  • Indications Embolism and thrombosis; Peripheral arterial disorders
  • Focus Therapeutic Use
  • Acronyms MASCOT
  • Sponsors Sanofi
  • Most Recent Events

    • 18 Dec 2008 Planned number of patients changed from 580 to 599 as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 13 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top